This is a Phase 1/2, open-label, multi-center study to assess the efficacy, safety,
tolerability, pharmacokinetics, including recommended phase 2 dose (RP2D) of HM43239
monotherapy in subjects with relapsed or treatment-refractory acute myeloid leukemia (AML).
- Institutional Review Board (IRB)-/Independent Ethics Committee (IEC)-approved written
Informed Consent including privacy language as per national regulations (e.g., HIPAA
Authorization for U.S. site) must be obtained from the subject or legally authorized
representative prior to any study-related procedures (including withdrawal of
prohibited medication, if applicable).
- Patient is ≥ 18 years of age (or country's legal age of majority if the legal age was
> 18 years) at the time of obtaining informed consent.
- Patient is defined as morphologically documented primary or secondary AML by the World
Health Organization (WHO) criteria (2016) and fulfills one of the following:
1. Refractory to at least 1 cycle of prior therapy
2. Relapsed after achieving remission with a prior therapy
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- Patient's interval from prior treatment to time of study drug administration is at
least 2 weeks for cytotoxic agents (except hydroxyurea given for controlling blast
cells), or at least 5 half-lives for prior experimental agents or noncytotoxic agents,
including immunosuppressive therapy post hematopoietic stem cell transplantation
- Patient must meet the following criteria as indicated on the clinical laboratory tests
1. Serum aspartate aminotransferase(AST) and alanine aminotransferase(ALT) ≤ 2.5×
institutional upper limit normal (ULN)
2. Total serum bilirubin ≤ 1.5× institutional ULN
3. Serum creatinine ≤ 1.5× institutional ULN or an estimated glomerular filtration
rate (eGFR) of > 60 ml/min as calculated by the Modification of Diet in Renal
Disease (MDRD) equation.
- Patient is suitable for oral administration of study drug and has minimum life
expectancy (≥ 3 months)
- Female patient must be either:
- Of non-child bearing potential
1. Post-menopausal (defined as at least 1 year without any menses) prior to
2. Documented surgically sterile or status post hysterectomy (at least 1 month prior
- Or, if of childbearing potential,
1. Must have a negative serum or urine pregnancy test at screening Φ , and
2. Must use two forms of birth control£ (at least one of which must be a barrier
method) starting at screening and throughout the study period and for 90 days
after the final study drug administration.
- Female patient must not be breastfeeding at screening and during the study period, and
for 90 days after the final study drug administration
- Female patient must not donate ova starting at screening and throughout the study
period, and for 90 days after the final study drug administration.
- Male patient and their female spouse/partners who are of childbearing potential must
be using highly effective contraception consisting of two forms of birth control£ (one
of which must be a barrier method) starting at screening and continue throughout the
study period and for 90 days after the final study drug administration.
- Male patient must not donate sperm starting at screening and throughout the study
period and for 90 days after the final study drug administration.
- Patient agrees not to participate in another interventional study while on treatment
Patients must not enter the study if any of the following exclusion criteria are fulfilled.
- Patient was diagnosed as acute promyelocytic leukemia (APL)
- Patient has BCR-ABL-positive leukemia
- Patient has active malignant tumors other than AML, or Myelodysplastic Syndrome (MDS).
- Patient has persistent non-hematological toxicities of ≥ Grade 2 (CTCAE v4.03), with
symptoms and objective findings, from prior AML treatment (including chemotherapy,
kinase inhibitors, immunotherapy, experimental agents, radiation, or surgery)
- Patient has had hematopoietic stem cell transplant (HSCT) and meets any of the
1. Has undergone HSCT within the 2 month period prior to the first study dose
2. Has clinically significant graft-versus-host-disease(GVHD) requiring treatment
3. Has ≥ Grade 2 persistent non-hematological toxicity related to the transplant
Donor lymphocytes infusion (DLI) is not permitted ≤ 30 days prior to the first
study dose or during the first two cycle of treatment on the study in Part A and
- Patient with symptomatic central nervous system (CNS) involvement of leukemia or other
CNS diseases related to underlying and secondary effects of malignancy.
- Patient has disseminated intravascular coagulation abnormality (DIC) Φ.
- Patient has had major surgery within 4 weeks prior to the first study dose.
- Patient has had radiation therapy within 4 weeks prior to the first study dose.
- Patient has congestive heart failure New York Heart Association (NYHA) class 3 or 4,
or patient with a history of congestive heart failure NYHA class 3 or 4 in the past,
unless a screening echocardiogram or multigated acquisition (MUGA) scan performed
within 3 months prior to study entry results in a left ventricular ejection fraction
(LVEF) that is ≥ 45% Φ.
- Any of the following cardiac abnormalities of history
1. Patient has any clinically important abnormalities in rhythm, conduction or
morphology of resting ECG, e.g., complete left bundle branch block, third-degree
heart block, second-degree heart block, or PR interval > 250milliseconds (ms).
2. Patient has a mean QT interval (QTc) by Friderica's method (QTcF) > 450ms in
three successive Screening measurements.
3. Patient has any factors that increase the risk of QTc prolongation or risk of
arrhythmic events, such as congenital long QT, syndrome, family history of long
4. Patient is unable or unwilling to discontinue concomitant use of drugs that are
known to prolong the QT interval.
- Patient with an active infection. Φ
- Patient is known to have human immunodeficiency virus infection.
- Patient has known active hepatitis B or C, or other active hepatic disorder Φ.
- Patient has any condition which, in the investigator's opinion, makes the patient
unsuitable for study participation.